Antibe Therapeutics Inc.
ATBPF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $48 | $26 | $24 | $31 |
| - Cash | $11 | $4 | $9 | $7 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $36 | $21 | $16 | $24 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$4 | -$5 | -$5 | -$3 |
| % Margin | – | – | – | – |
| Net Income | -$4 | -$5 | -$6 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.08 | -0.1 | -0.11 | -0.067 |
| % Growth | 20% | 9.1% | -63.2% | – |
| Operating Cash Flow | -$4 | -$6 | -$5 | -$3 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4 | -$6 | -$5 | -$3 |